WESTBROOK, ME (May 27, 2021) – The 2021 LabAutomation Online event will be presenting a wide variety of posters, webinars, and virtual exhibit booths. Dr. Nathaniel Hentz, Artel’s Director of Scientific Market Development, will be offering the presentation “Evaluating Disposable Pipette Tip Performance: Guided by Science” on behalf of Analis Scientific Instruments – Artel’s exclusive territory representative who will also have a booth at the event. Many laboratories are currently experiencing a significant shortage of disposable pipette tips. This has resulted in scientists switching to alternative brands or reusing tips. Without properly qualifying such approaches the assays performed with these tips often suffer from poor data quality, lot to lot variability, or sporadic failures. How can a laboratory address these issues?
The webinar addresses the attributes that affect pipette tip quality during manufacturing and how brands may perform differently, the uncertainties involved with tip reuse, and concludes with advice on how to design and institute an effective tip performance verification program. This quantitative approach provides you with data allowing you to make informed decisions. By implementing a verification program to qualify alternative sources of tips or methods of tip use you can ensure that the tips meet your specifications before embarking on large screenings or diagnostic testing campaigns.
Evaluating Disposable Pipette Tip Performance: Guided by Science
Date: Tuesday, June 15, 2021
Time: 9:00am EDT (3:00pm CEST)
What you will learn:
Dr. Nathaniel Hentz is the Director of Scientific Market Development at Artel, where his principal focus is development of methods to help customers achieve optimized efficiency and quality in their assay workflows. Dr. Hentz previously served as Assistant Director of the BTEC Analytical Lab at North Carolina State University. In that role he taught both undergraduate and graduate level courses as well as industry short courses focused on biopharmaceutical assay development and validation. Dr. Hentz’s tenure in the HTS industry includes a key role in supporting automated screening systems within the Lead Discovery group at Bristol-Myers Squibb and responsibilities for developing screens at Eli Lilly.